Your browser doesn't support javascript.
loading
Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields.
Pandey, Manjari; Xiu, Joanne; Mittal, Sandeep; Zeng, Jia; Saul, Michelle; Kesari, Santosh; Azadi, Amir; Newton, Herbert; Deniz, Karina; Ladner, Katherine; Sumrall, Ashley; Korn, W Michael; Lou, Emil.
Afiliación
  • Pandey M; West Cancer Center and Research Institute, Memphis, Tennessee, USA.
  • Xiu J; Caris Life Sciences, Phoenix, Arizona, USA.
  • Mittal S; Virginia Tech Carilion School of Medicine, Roanoke, Virginia, USA.
  • Zeng J; Caris Life Sciences, Phoenix, Arizona, USA.
  • Saul M; Caris Life Sciences, Phoenix, Arizona, USA.
  • Kesari S; Pacific Neuroscience Institute, Saint John's Cancer Institute, Santa Monica, California, USA.
  • Azadi A; Arizona Oncology Biltmore, Phoenix, Arizona, USA.
  • Newton H; Neuro-Oncology Center, Advent Health Cancer Institute, Orlando, Florida, USA.
  • Deniz K; Division of Hematology, Oncology and Transplantation, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.
  • Ladner K; Division of Hematology, Oncology and Transplantation, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.
  • Sumrall A; Levine Cancer Institute, Charlotte, North Carolina, USA.
  • Korn WM; West Cancer Center and Research Institute, Memphis, Tennessee, USA.
  • Lou E; Division of Hematology, Oncology and Transplantation, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.
Neurooncol Adv ; 4(1): vdac096, 2022.
Article en En | MEDLINE | ID: mdl-35821680

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Año: 2022 Tipo del documento: Article